Natural Frequencies of Levodopa-Induced Dyskinesia in Parkinson's Disease. [PDF]
Ann Clin Transl NeurolABSTRACT Objectives Abnormal involuntary movements, known as dyskinesias, are common complications of levodopa treatment in patients with Parkinson's disease and can significantly impair quality of life. The underlying pathophysiology remains unclear, and current therapeutic options are limited.
Isaias IU +3 more
europepmc +2 more sources
A novel approach to the management of levodopa-induced dyskinesia using deep transcranial magnetic stimulation: A case report [PDF]
Journal of International Medical ResearchLevodopa-induced dyskinesia remains one of the most prevalent and disabling complications in patients with Parkinson's disease receiving long-term levodopa therapy.
In-Uk Song, Byungseok Kim, Yong An Chung
doaj +2 more sources
Placebo Effect in Levodopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis. [PDF]
Mov Disord Clin PractAbstract Background Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.
Correa LVS +5 more
europepmc +2 more sources
Serum ferritin, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio are associated with levodopa-induced dyskinesia severity in Parkinson’s disease [PDF]
BMC NeurologyBackground Levodopa-induced dyskinesia (LID) is a common motor complication of Parkinson’s disease (PD), yet peripheral biological factors associated with dyskinesia severity remain insufficiently characterized.
Farrukh Saidvaliyev +10 more
doaj +2 more sources
Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming [PDF]
Frontiers in Neuroscience, 2023 BackgroundA rat model of levodopa-induced dyskinesia (LID) showed enlarged axon terminals of striatal direct pathway neurons in the internal segment of the globus pallidus (GPi) with excessive gamma-aminobutyric acid (GABA) storage in them.
Takashi Nakamura +7 more
doaj +2 more sources
Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment [PDF]
Biomedicines, 2023 Mitophagy is an important process that participates in mitochondrial quality control. Dysfunctions in this process can be caused by mutations in genes like PRKN and are associated with the development and progression of Parkinson’s Disease (PD). The most
Ana Gabrielle Bispo +7 more
doaj +2 more sources
Cells, 2021 Dyskinesias are characterized by abnormal repetitive involuntary movements due to dysfunctional neuronal activity. Although levodopa-induced dyskinesia, characterized by tic-like abnormal involuntary movements, has no clinical treatment for Parkinson’s ...
Luca Pagliaroli +9 more
doaj +1 more source
Frontiers in Neurology, 2021 Objective: This study aimed to evaluate the direct anti-dyskinesia effect of deep brain stimulation (DBS) of subthalamic nucleus (STN) on levodopa-induced on-dyskinesia in Parkinson's disease (PD) patients during the early period after surgery without ...
Jiping Li +3 more
doaj +1 more source
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies. [PDF]
Cells, 2022 Kwon DK, Kwatra M, Wang J, Ko HS.
europepmc +2 more sources
Frontiers in Neurology, 2021 After long-term use of levodopa, Parkinson's patients almost inevitably develop dyskinesia, a kind of drug side effect manifesting as uncontrollable choreic movements and dystonia, which could be crippling yet have limited therapeutic options ...
Yi Wu +9 more
doaj +1 more source